ALEMBIC PHARMACEUTICALS LTD SHARE PRICE [LIVE]
| Open: | |
| High: | |
| Low: |
| MKT Cap: | |
| 52-wk High: | |
| 52-wk Low: |
| Prev close: | |
| P/E: | |
| Div yield: |
Fundamental analysis
What is not working for the company?
What is working for the company?
| Name | Dec 22 | Sep 22 |
|---|---|---|
| Promoters (Change:-0.00) | 69.61% | 69.61% |
| FIIs (Change:-0.33) | 4.99% | 5.32% |
| Mutual Funds (Change:0.51) | 5.87% | 5.36% |
| Insurance Companies (Change:-0.43) | 6.6% | 7.03% |
| Other DIIs (Change:0.13) | 0.28% | 0.15% |
| Non Institution (Change:0.12) | 12.65% | 12.53% |
Similar Stocks
Return Calculator
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in ALEMBIC PHARMACEUTICALS LTD
Months ago
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
APLLTD News
Frequently Asked Questions
What is the Share price of ALEMBIC PHARMACEUTICALS LTD. (APLLTD)?
Can I buy ALEMBIC PHARMACEUTICALS LTD. (APLLTD) shares?
How do I buy ALEMBIC PHARMACEUTICALS LTD. (APLLTD) from Angel One?
- Direct investment: You can buy ALEMBIC PHARMACEUTICALS LTD. (APLLTD) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to ALEMBIC PHARMACEUTICALS LTD. (APLLTD) shares.
In which sector do ALEMBIC PHARMACEUTICALS LTD. (APLLTD) belong?
Is Alembic Pharmaceuticals a Debt free Company?
No, Alembic Pharmaceuticals is not a debt free company.
What is the main business of Alembic Pharmaceuticals?
The main business of Alembic Pharmaceuticals is to develop and manufacture generic pharmaceutical substances, intermediates, and pharmaceutical products.
Who are the promoters of Alembic Pharmaceuticals?
The main promoters of Alembic Pharmaceuticals include Nirayu Limited, Alembic Limited, Chirayu Ramanbhai Amin, Malika Chirayu Amin, Pranav Chirayu Amin, Shaunak Chirayu Amin, Udit Chirayu Amin, Inaaya Shaunak Amin, Naintara Shaunak Amin, Ranvir Pranav Amin, and Samira Pranav Amin.
What are the Subsidiaries that comes under Alembic Pharmaceuticals?
The main subsidiaries that come under Alembic Pharmaceuticals are Alembic Pharmaceuticals Inc., Alembic Global Holding SA, Alembic Pharmaceuticals Australia Pty Ltd, Alembic Pharmaceuticals Europe Ltd., Alnova Pharmaceuticals SA, Alembic Labs LLC, Alembic Pharmaceuticals Canada Ltd., and Genius LLC.
About APLLTD
Today's live share price for ALEMBIC PHARMACEUTICALS LTD is NSE: ₹ 496.35, BSE: ₹ 491.25 with a current market capitalization of .
Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in Pharamceulicals business. As per the scheme of arrangement, the "Pharmaceutical Undertaking" of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010. In April 15, 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement, the shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd. In September 20, 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. During 2014, the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.". During 2015, the companies associate signs exclusive agreement with Novartis.
Read more
